Cabaletta Bio (CABA) Price & Analysis

Compare

1,178 Followers

CABA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.99 - $6.14

Previous CloseN/A

Volume846.62K

Average Volume (3M)1.25M

Market Cap

$145.43M

Enterprise Value-$75.74M

Total Cash (Recent Filing)$194.68M

Total Debt (Recent Filing)$24.89M

Price to Earnings (P/E)―

Beta3.95

Next Earnings

Nov 12, 2025

EPS Estimate

-0.49

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.73

Shares Outstanding91,465,230

10 Day Avg. Volume1,778,219

30 Day Avg. Volume1,248,769

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.52

Enterprise Value/Revenue-46.24

Enterprise Value/Gross Profit135.73

Enterprise Value/Ebitda0.55

Forecast

1Y Price Target

$12.00

Price Target Upside684.31% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Clinical DataThe company presented compelling clinical data recently reported across myositis, lupus, and scleroderma cohorts at EULAR 2025.

Clinical TrialsAccelerating enrollment lets rese-cel move towards registrational cohorts in a range of indications, though myositis stays in focus.

Regulatory DevelopmentsCabaletta has reached alignment with the FDA on the pivotal trial design for rese-cel in myositis.

Bears Say

Capital NeedsThe capital needs remain a clear headwind for the company given it has few major stock moving catalysts in the near term.

Financial ConcernsDespite the recent financing, CABA's cash overhang persists, and the company will need to raise again to reach rese-cel's pivotal readouts for myositis, absent any strategic partnering.

Market SentimentShares are down -39% YTD as investor skepticism persists on rese-cel's safety and its differentiation from other autoCART programs.

Cabaletta Bio News

Cabaletta Bio price target lowered to $16 from $25 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Cabaletta Bio (CABA) to $16 from $25 and keeps a...

21d ago

CABA

Cabaletta Bio price target lowered to $2 from $3 at Wells Fargo

Wells Fargo analyst Derek Archila lowered the firm’s price target on Cabaletta Bio (CABA) to $2 from $3...

21d ago

CABA

Cabaletta Bio files $240M mixed securities shelf

08:27 EDT Cabaletta Bio (CABA) files $240M mixed securities shelf Published first on TheFly – the ultimate source...

22d ago

CABA

Cabaletta Bio reports Q2 EPS (73c), consensus (61c)

“We achieved significant progress advancing rese-cel in the first half of 2025, including aligning with the FDA on...

22d ago

CABA

Cabaletta Bio sees cash runway into 2H26

As of June 30, 2025, Cabaletta had cash, cash equivalents and short-term investments of $194.7 million, compared to...

22d ago

CABA

Cabaletta Bio Reports Progress in Clinical Trials

Cabaletta Bio, Inc. ( ($CABA) ) has released its Q2 earnings. Here is a breakdown of the information...

21d ago

CABA

Cabaletta Bio: Strong Financial Position and Strategic Clinical Advancements Drive Buy Rating

TD Cowen analyst Phil Nadeau has maintained their bullish stance on CABA stock, giving a Buy rating today....

21d ago

CABA

Cabaletta Bio’s Promising Clinical Study on CABA-201 for Myasthenia Gravis

Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. RESET-MG is a Phase 1/2 open-label...

21d ago

CABA

Cabaletta Bio’s Promising Study on CABA-201 for Myasthenia Gravis: A Potential Game-Changer

Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. Cabaletta Bio, Inc. is conducting a...

23d ago

CABA

Cabaletta Bio’s RESET-SLE Study: A Promising Step in Lupus Treatment

Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. RESET-SLE is a Phase 1/2 open-label...

1M ago

CABA

Cabaletta Bio’s RESET-MG Study: A Potential Game-Changer for Myasthenia Gravis Treatment

Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. Study Overview: The RESET-MG study, officially...

1M ago

CABA

Cabaletta Bio’s RESET-Myositis Study: A Promising Step in Autoimmune Treatment

Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. RESET-Myositis is a Phase 1/2 open-label...

1M ago

CABA

Cabaletta Bio’s RESET-MG Study: A Promising Step in Myasthenia Gravis Treatment

Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. RESET-MG is a clinical study conducted...

1M ago

CABA

Cabaletta Bio’s RESET-Myositis Study: A Potential Game-Changer in Autoimmune Disease Treatment

Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. Study Overview: The RESET-Myositis study, officially...

1M ago

CABA

CABA FAQ

What was Cabaletta Bio’s price range in the past 12 months?

Cabaletta Bio lowest stock price was $0.98 and its highest was $6.14 in the past 12 months.

What is Cabaletta Bio’s market cap?

Cabaletta Bio’s market cap is $145.43M.

When is Cabaletta Bio’s upcoming earnings report date?

Cabaletta Bio’s upcoming earnings report date is Nov 12, 2025 which is in 75 days.

How were Cabaletta Bio’s earnings last quarter?

Cabaletta Bio released its earnings results on Aug 07, 2025. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.65 by -$0.08.

Is Cabaletta Bio overvalued?

According to Wall Street analysts Cabaletta Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cabaletta Bio pay dividends?

Cabaletta Bio does not currently pay dividends.

What is Cabaletta Bio’s EPS estimate?

Cabaletta Bio’s EPS estimate is -0.49.

How many shares outstanding does Cabaletta Bio have?

Cabaletta Bio has 91,465,230 shares outstanding.

What happened to Cabaletta Bio’s price movement after its last earnings report?

Cabaletta Bio reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.65. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Cabaletta Bio?

Currently, no hedge funds are holding shares in CABA

Cabaletta Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

-76.34%

Trailing 12-Months

Asset Growth

3.26%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cabaletta Bio

Cabaletta Bio (CABA) is a biotechnology company focused on developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's core product pipeline involves utilizing its proprietary Chimeric AutoAntibody Receptor (CAAR) T cell technology to target and eliminate disease-causing B cells while preserving healthy B cells, aiming to provide a transformative impact on patients' lives.

Cabaletta Bio (CABA) Earnings & Revenues

Historic Earnings Reports

CABA Stock 12 Month Forecast

Average Price Target

$12.00

▲(684.31% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","23":"$23","5.75":"$5.75","11.5":"$11.5","17.25":"$17.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5.75,11.5,17.25,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,3.0215384615384613,4.603076923076923,6.184615384615384,7.766153846153845,9.347692307692306,10.929230769230768,12.51076923076923,14.09230769230769,15.673846153846151,17.255384615384614,18.836923076923075,20.41846153846154,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,2.252307692307692,3.0646153846153847,3.876923076923077,4.68923076923077,5.501538461538463,6.313846153846153,7.126153846153846,7.938461538461539,8.750769230769231,9.563076923076924,10.375384615384617,11.187692307692307,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,1.483076923076923,1.5261538461538462,1.5692307692307692,1.6123076923076922,1.6553846153846155,1.6984615384615385,1.7415384615384615,1.7846153846153845,1.8276923076923077,1.8707692307692307,1.913846153846154,1.956923076923077,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.88,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.64,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >